This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tianyin Pharmaceutical's CEO Discusses F3Q 2011 Results - Earnings Call Transcript

Gross Margin for FQ3 was 43.6% as compared to 52.8% for the quarter ended March 31 st 2010. The decrease in gross margin was attributable to the average 15% TMT distribution revenue. In addition, the pricing pressure on our generic product also leads to the gross margin reduction.

During this quarter our 56 product organic portfolio delivered approximately 51.4% gross margin, about 1.4% lower than the gross margin of 52.8% from a year earlier.

Given these trends we anticipate that our overall gross margin in the near term on a quarter to quarter comparison base may trend lower but on a sequential basis should stabilize and improve depending upon the revenue mix percentage of TMT revenue, upcoming JCM macrolide API revenue as compared to the proprietary portfolio's revenue performance.

Operating Expenses for FQ3 were $5.8 million compared with $4.8 million for the quarter ended March 31 st 2010. Continuing sales payroll and marketing expenses are the main components of the operating expenses.

Net Income was $3.7 million for the quarter ended March 31 st 2011 as compared to net income of $2.9 million for FQ3 2010, a net increase of $.8 million or 27.6% year over year.

Net profit margins for the quarter ended March 31 st 2011 decreased to 14.9% from 18.3% for the quarter ended March 31 st 2010 mainly attributable to one; recent pricing pressure on the generic pharmaceutical business, two; lower margin TMT distribution revenue, three; increase of income tax provision to 25% starting January 2011 from the previous 15% for Chengdu Tianyin on the expiration of the three year tax benefit for high tech enterprise. We expect the stabilization of the net profit margin at approximately 15% going forward under the current condition.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,745.98 -5.41 -0.03%
S&P 500 2,108.63 +0.06 0.00%
NASDAQ 5,128.7850 +17.0520 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs